Research

The Defend 1050 achieved a 4.53 log10 reduction of live SARS-CoV-2 virus, which equates to a 99.997% percentage reduction, in 30 minutes. The live SARS-CoV-2 virus was not detectable after 30 minutes.

The Novaerus Defend 400 achieved an average live SARS-CoV-2 virus reduction of 8.76 x 103 TCID50/mL, which equates to a 99.86% percentage reduction, after 45 minutes. A net reduction of 99.75% was achieved with the device operating for a total of the 45 minutes time point.

Novaerus Defend 1050 was shown to reduce MS2 bacteriophage virus, a surrogate for SARS-CoV-2, by 99.99% in 15 minutes at Aerosol Research and Engineering Laboratories.

Novaerus Defend 400 was shown to reduce MS2 bacteriophage, a surrogate for SARS-CoV-2, by 99.9995% in 45 minutes at Aerosol Research and Engineering Laboratories in Kansas.

The Protect 200 (NV200/330) was shown to reduce MS2 bacteriophage, a surrogate for SARS-CoV-2, by 99.991% in 180 minutes at Aerosol Research and Engineering Laboratories in Kansas.

Novaerus NV950 (Protect 800/900) cleaned 100% of the air in a room of 22.65m³ (800 ft³) in 21-24 minutes, dependent on fan speed at the Cork Institute of Technology in Cork, Ireland.

Novaerus Protect 200 (NV200/330) passed standard UL testing with a maximum ozone concentration of 0.037 ppm at UL Environment in Georgia.

Novaerus Protect 800 passed standard UL testing with a maximum ozone concentration of 0.017 ppm with fan on high speed setting and 0.020 ppm with fan on low speed setting at Intertek in New York.

Novaerus Protect 900 passed standard UL testing with a maximum ozone concentration of 0.026 ppm with fan on high speed setting and 0.006 ppm with fan on low speed setting at UL Environment in Georgia, USA.

Novaerus Protect 800/900 was shown to reduce overall allergens by 41.16%, including house dust mites, feline dander, canine dander, and pollen at Indoor Biotechnologies Ltd. in Cardiff, UK.

Novaerus Defend 1050 was shown to reduce aerosolized Aspergillus niger spores at the Aerosol Research and Engineering Laboratories.

The Defend 1050 showed a 4-log (99.99%) reduction in Bacillus Globigii endospores within 15 minutes, which was maintained over the prolonged operation (24 hours).

The Defend 400 achieved a net LOG reduction of Bacillus Globigii endospores after 45 minutes of 4.55 which is equivalent to a net percent reduction of 99.9969%.

Novaerus Protect 800/900 was shown to reduce aerolized biologicals: Staphylococcus epidermidis (99.87% reduction), MS2 bacteriophage (99.99% reduction), Aspergillus niger fungus (99.1% reduction), and Bacillus subtilis endospores (86.63% reduction) at the Aerosol Research and Engineering Laboratories.

Novaerus Defend 1050 was shown to reduce 99.6% of airborne C. difficile within the first 20 minutes of operation and >99.9% after 40 minutes at the Airmid Health Group Ltd. in Ireland.

Novaerus Defend 1050 was shown to reduce 99.9% of airborne Influenza A within the first 10-20 minutes of operation at the Airmid Health Group Ltd. in Ireland.

The Protect 200 (NV200/330) was effective at removing 51.8% of the Influenza H1N1 virus from the air after 1 passage (or 44 seconds) through the device.

Novaerus Defend 1050 had an average net LOG reduction of 2.52 LOG across four tests and formaldehyde levels reached 0.00 ppm in an average of 1.1 minutes at the Aerosol Research and Engineering Laboratories.

Novaerus Protect 800/900 was shown to reduce formaldehyde by 85% during a 14-hour testing experiment using Avomeen Analytical Services in Michigan.

Defend 1050 was able to reduce the concentration of human parainfluenza type 3 (HPIV3) (renamed human respirovirus 3), a surrogate for Measles virus, by 99.87% after 25 minutes at Airmid Healthgroup in Ireland.

Novaerus Protect 800/900 reduced 99.99% of methicillin-resistant Staphylococcus aureus (MRSA) bacteria over the course of four hours at Microbac Laboratories, Inc. in North Carolina.

This study was conducted by the Academic Health Science Networks (AHSN) as part of the National Health Services Environmental decontamination framework evaluation in the UK.

The Defend 400 device was evaluated against Micrococcus luteus bacteria over 1 hour in a room setting to determine the disinfection capabilities against aerosolised bacteria. 

Conducted by the Academic Health Science Networks (AHSN), this study is part of the National Health Services Environmental decontamination framework evaluation in the UK.

The effectiveness of the Defend 1050 device was evaluated against Micrococcus luteus bacteria. Tests mimicked real-world settings to determine the disinfection capabilities against aerosolised bacteria in a room.

Novaerus Defend 1050 was shown to reduce MS2 bacteriophage virus, a surrogate for SARS-CoV-2, RSV, Influenza A, and Norovirus, by 99.99% in 15 minutes at Aerosol Research and Engineering Laboratories.

Novaerus Defend 1050 was shown to reduce the concentration of M. smegmatis (surrogate for M. tuberculosis) by 97% after 30 minutes of operation at the Airmid Healthgroup.

The Novaerus Protect 200 (NV200/330) rendered all airborne Mycobacterium tuberculosis non-viable at Qualilife Diagnostics in India.

Novaerus Defend 1050 reduced the chamber concentration of Nitrogen Dioxide (NO₂) to 0.0 ppm at 7.5 minutes in all three trials at Aerosol Research and Engineering Laboratories.

Novaerus Defend 1050 removed 99% of PM2.5 within 6.26 minutes and 99% of PM1.0 within 6.33 minutes at Camfil Laboratories – Tech Center in Sweden.

The Defend 400 reduced PM 1 by 99.99% in 26 minutes with an eCADR of 340.7 m³/h. PM 2.5 was reduced by 99.99% in 25.9 minutes with an eCADR of 341.0 m³/h.

Novaerus Defend 1050 was shown to reduce phi X 174 virus, a surrogate for Hepatitis B23, Hepatitis C23 and HIV2 by 98.8% in 30 minutes at the Korea Testing Laboratory.

The Defend 400 achieved greater than a log-4 reduction (>99.99%) of Staphylococcus epidermidis after 45 minutes.

Novaerus Defend 1050 was shown to reduce Staphylococcus epidermidis bacteria by 99.9% in 60 minutes at the Korea Testing Laboratory.

Novaerus Defend 1050 achieved a microbial cell reduction of 99.94% of Staphylococcus epidermidis within 15 minutes of operation at the Novaerus Research and Development Labs.

Novaerus shown to reduce 95% of Staphylococcus epidermidis aerosol contamination in 30 minutes at the University of Huddersfield in England.

Novaerus Defend 1050 achieved 90% VOC removal after 6 - 16 minutes, dependent on fan speed at Camfil Laboratories – Tech Center in Sweden.

The Defend 1050 was shown to reduce 99.99% of aerolized Enterobacter cloacae, Salmonella enterica and Listeria innocua in 15 minutes and exceeded a 6 net log reduction in 20 minutes.

WellAir’s Novaerus Protect 800/900 air cleaning device was used in the University Hospitals Birmingham's Hospital Infection Research Laboratory — results showed a statisctially significant reduction in total viable counts of microbial bioburden.

A Hospital in Glen Echo, MD evaluates WellAir’s Novaerus Defend 400 air cleaning device in an operating room — results showed a substantial reduction in airborne bacterial bioburden over an 2-day period.

The use of the FDA-Cleared Defend 1050 portable stand-alone air cleaner in a hospital breakroom at Northwell Health in New York (North Shore University Hospital) showed a substantial reduction in airborne bacterial bioburden overall.

During the 5 consecutive days at Cape Regional Urgent Care in New Jersey, the Defend 400 significantly reduced total bacterial count by 52%, which included a 60% reduction in opportunistic pathogens and a 43% reduction in pathogenic bacteria. 

WellAir’s Novaerus devices help to reduce the microbial load in the air and surfaces and thus hospital-acquired infections. This intervention study was conducted in two similar ICUs in Turkey between May to November of 2020.

Novaerus reduces VOCs by 93%, airborne bacteria by 87% and moulds by 67% at two Fresenius Dialysis Centres in Portugal.

Novaerus shown to reduce airborne Staphylococcus by 100%, airborne bacteria by 89% and airborne fungi by 87% at the Bucharest Emergency University Hospital in Romania.

Novaerus reduces staff sickness, ward odours, infections and antibiotic use. Wards with Novaerus have had no outbreaks of MRSA, C. diff, influenza, or norovirus since installation at the Leopardstown Park Hospital in Dublin.

Novaerus reduces environmental surface MRSA by 97% and reduces environmental surface TVC and environmental air MRSA at the Royal Free Hospital in London.

Novaerus shown to reduce airborne bacteria and fungi 96% at the “Dr V. Babes” Hospital of Infectious and Tropical Diseases in Bucharest, Romania.

Novaerus plasma technology shown to significantly reduce number of microorganisms at Brothers Hospitallers of Saint John of God Hospital in Łódź, Poland.

Novaerus shown to reduce bacterial loads on high surfaces and window sills as well as reduce overall infection rates by 23% compared to increase of infection rates by 35% in control section at Rigshospitalet in Copenhagen, Denmark.

Novaerus reduces bacterial colony count in both the rooms that were being used and those that were empty at Ain Shams University in Cairo, Egypt.

Novaerus devices effectively reduce the number of airborne pathogens by 61% in the admission room of the Paediatric Department and by 19% in the Clinic of Pulmonology/Tuberculosis and Pulmonary Diseases at Międzyrzecz Hospital in Międzyrzecz, Poland.

Novaerus reduces CFU rates by 82% and fungi count by 93% after 2 months of operation at the Uzsoki Hospital in Budapest, Hungary.

Novaerus devices significantly reduce number of microorganisms as well as eliminate unwanted odours at Specialised Hospital in Chorzów, Poland.

The evaluation measured the efficacy of the Protect 200 in rendering airborne five clinical isolates of Acinetobacter species. It was observed that positive control blood agar and MacConkey’s agar plates showed growth, whereas inoculated plates showed no growth in 48 hours.

In the midst of the pandemic, life's pace slowed significantly, impacting various sectors. However, the operations of the world's blood banks, including the Beijing Red Cross Blood Center, remained crucial. To ensure the uninterrupted functioning of blood banks, Novaerus air disinfection devices, powered by the patented NanoStrike™ air disinfection technology, were deployed.

This 20-month study compares the total number of respiratory nosocomial infections before and after implementation of the Novaerus technology.

This 35-month study compares the total number of respiratory nosocomial infections and infection rates before and after each implementation of the Novaerus technology.

Belgium was one of the worst-hit countries in Europe by the COVID-19 pandemic, with 2,100 deaths per million people. However, the tide began to turn in 2021 as the Belgian government implemented a successful vaccination programme, with almost 13.5 million doses administered to date. The swift vaccine rollout, along with the marked reduction in infection rates, increasingly led to calls for the reopening of hospitality venues, including the nightlife sector.

This 24-month study compares the total number of respiratory nosocomial infections before and after implementation of the Novaerus technology at Edgehill Nursing and Rehabilitation Center (ENRC) in Pennsylvania.

Since 2014, the Haus an der Traisen nursing home in St. Pölten (Austria) have supplemented their existing hygiene protocols with Novaerus air purification units to help control infection and reduce odour.

This 24-month study compares the total number of repeat infections, nosocomial C. difficile infections, and nosocomial respiratory infections before and after implementation of the Novaerus technology at Hialeah Nursing and Rehab Center (HNRC) in Florida.

Linde Healthcare, a Vienna-based healthcare company, had no existing healthy air solution in place for its 16 person open floorplan office space. Curious about Novaerus’s innovative technology, they reached out to learn more.

This 24-month study compares the total number of nosocomial respiratory infections and nosocomial C. difficile infections before and after implementation of the Novaerus technology at Manchester Manor Health Care Center (MMHCC) in Connecticut.

As COVID-19 rapidly spread across the globe, healthcare facilities around the world had to adapt. For Masfiv, a newly built medical centre specializing in reproductive medicine and gynaecological health, this meant maintaining minimal essential reproductive care services while containing the spread of coronavirus. Masfiv established a range of COVID-19 protocols including 24/7 air disinfection technology by Novaerus. 

This 24-month study compares the total number of nosocomial respiratory infections before and after implementation of the Novaerus technology at Meadow View Nursing Center (MVNC) in Pennsylvania.

This 28-month study compares the total number of nosocomial respiratory infections and nosocomial C. difficile infections before and after implementation of the Novaerus technology at Naamans Creek Country Manor (NCCM) in Pennsylvania.

This 29-month study compares the average monthly rate of nosocomial respiratory infections before and after implementation of the Novaerus technology at Page Rehabilitation and Healthcare Center (PRHC) in Florida.

Patki Hospital, an IVF centre specialized in obstetrics, infertility and gynaecology in India, were looking for a solution to reduce airborne VOC and infection load in their lab. After investigating various options, the hospital decided to deploy a Novaerus Defend 1050. The result; improved outcomes and air quality. 

Sante International has provided solutions to the Romanian healthcare industry since 1992 and has partnered with Novaerus since 2014. Over a 3-month period, they proved Novaerus technology is more efficient and safer with no maintenance and at a low cost.

As part of a trial to measure background pollution and pathogenic organisms, Novaerus units were placed in 4 locations in the University of Szeged’s Department of Geriatrics and Chronic Diseases of the Internal Medicine Clinic No. 1. The medical clinic was interested in improving overall air quality in the geriatric and chronic disease wards.

This 24-month study compares the total number of nosocomial respiratory infections before and after implementation of the Novaerus technology at Vernon Manor Health Care Center (VMHCC) in Connecticut.

This 23-month study compares the total number of nosocomial respiratory infections before and after implementation of the Novaerus technology.

Two weeks after installation, Wassan Dental (Oman) staff observed a noticeable reduction in odour. Staff were reassured to know that Novaerus was operating continuously in the background to eliminate VOC, infectious pathogens and allergens from the air.

In Hungary, the COVID-19 health crisis prompted the establishment of mandatory specialized facilities for all in-patient healthcare institutions. For Uzsoki Hospital, a busy, high-traffic hospital in Budapest, this meant transforming its Department of Pulmonology to a ward specially designed to deal with the virus.

As Covid-19 spread around the world, live music events everywhere were cancelled or postponed. TradFest Temple Bar, an annual live music festival celebrating Irish music and culture, reimagined their iconic event with the help of Novaerus air disinfection technology from WellAir.